Literature DB >> 30544027

Indications leading to termination of pregnancy between 22+0 and 31+6 weeks of gestational age in France: A population-based cohort study.

Isabelle Monier1, Nathalie Lelong2, Pierre-Yves Ancel2, Alexandra Benachi3, Babak Khoshnood2, Jennifer Zeitlin2, Béatrice Blondel2.   

Abstract

OBJECTIVE: To estimate the prevalence and indications of terminations of pregnancy (TOP) between 22+0 and 31+6 weeks of gestational age in France and to examine the characteristics of women by indication of TOP. STUDY
DESIGN: From the EPIPAGE 2 population-based cohort study of preterm births in France in 2011, we selected 5009 singleton live births, stillbirths and TOP that occurred between 22 and 31 weeks. We estimated the proportion of TOP by gestational age. We then classified terminations by indications into 4 categories: fetal anomalies (TOPFA), preterm premature rupture of the membranes (PPROM), maternal conditions and fetal growth restriction (FGR). We also classified TOPFA by type of anomaly. Maternal characteristics were compared between TOPFA and TOP for maternal or fetal conditions without congenital anomaly.
RESULTS: 23.1% of all births and 54.3% of stillbirths were terminations. The proportion of terminations was 36.9% of all births at 22 weeks, 50.2% at 24 weeks and <10% at 30-31 weeks. 85.8% of terminations were for fetal anomaly, 4.4% for PPROM, 6.1% for maternal complications and 3.7% for severe FGR. Compared to women with a TOPFA, those with a termination for maternal or fetal conditions were more often nulliparous, single, African, obese, smokers and covered by non-standard insurance for women in socially deprived circumstances.
CONCLUSION: In France, there is a high proportion of TOP of which 14% are for indications other than congenital anomalies. Because rates of terminations have an impact on very preterm birth and perinatal mortality rates, studies on pregnancy outcome should report all terminations, not only those for congenital anomalies.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EPIPAGE 2; Preterm births; Stillbirths; Terminations of pregnancy

Mesh:

Year:  2018        PMID: 30544027     DOI: 10.1016/j.ejogrb.2018.11.021

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  5 in total

1.  Birth outcomes between 22 and 26 weeks' gestation in national population-based cohorts from Sweden, England and France.

Authors:  Andrei S Morgan; Jennifer Zeitlin; Karin Källén; Elizabeth S Draper; Karel Maršál; Mikael Norman; Fredrik Serenius; Stef van Buuren; Samantha Johnson; Valérie Benhammou; Véronique Pierrat; Monique Kaminski; Laurence Foix L'Helias; Pierre-Yves Ancel; Neil Marlow
Journal:  Acta Paediatr       Date:  2021-09-12       Impact factor: 4.056

Review 2.  Perinatal post-mortem ultrasound (PMUS): radiological-pathological correlation.

Authors:  Susan C Shelmerdine; Neil J Sebire; Owen J Arthurs
Journal:  Insights Imaging       Date:  2019-08-21

3.  Analysis of Factors Associated With Body Mass Index at Ages 18 and 36 Months Among Infants Born Extremely Preterm.

Authors:  Yayoi Murano; Hiromichi Shoji; Naho Ikeda; Natsuki Okawa; Kuniyoshi Hayashi; Masato Kantake; Naho Morisaki; Toshiaki Shimizu; Stuart Gilmour
Journal:  JAMA Netw Open       Date:  2021-10-01

4.  Clarity and consistency in stillbirth reporting in Europe: why is it so hard to get this right?

Authors:  Mika Gissler; Mélanie Durox; Lucy Smith; Béatrice Blondel; Lisa Broeders; Ashna Hindori-Mohangoo; Karen Kearns; Rumyana Kolarova; Marzia Loghi; Urelija Rodin; Katarzyna Szamotulska; Petr Velebil; Guy Weber; Oscar Zurriaga; Jennifer Zeitlin
Journal:  Eur J Public Health       Date:  2022-04-01       Impact factor: 3.367

5.  Stillbirth as left truncation for early neonatal death in California, 1989-2015: a time-series study.

Authors:  Tim A Bruckner; Samantha Gailey; Abhery Das; Alison Gemmill; Joan A Casey; Ralph Catalano; Gary M Shaw; Jennifer Zeitlin
Journal:  BMC Pregnancy Childbirth       Date:  2021-07-02       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.